Ratings by Wolfe Research (Rudy Li)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/27/2026 | MapLight Therapeutics | MPLT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Outperform (N/A) |
33.41 (37.75) |
12.99% | Details | |
| 5/22/2026 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
21.54 (26.93) |
25.02% | Details | |
| 5/22/2026 | Compass Pathways | CMPS | New Coverage | Outperform (N/A) |
11.59 (10.97) |
-5.35% | Details | |
| 5/22/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
12.30 (12.86) |
4.55% | Details | |
| 3/31/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Peerperform (Outperform) |
27.58 (40.50) |
46.85% | Details | |
| 2/24/2026 | uniQure BV | QURE | New Coverage | Peerperform (N/A) |
23.43 (40.36) |
72.26% | Details | |
| 2/24/2026 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
34.29 (29.03) |
-15.34% | Details | |
| 2/24/2026 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
42.23 (63.75) |
50.96% | Details | |
| 2/24/2026 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
183.72 (229.44) |
24.89% | Details | |
| 2/24/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
128.63 (181.01) |
40.72% | Details | |
| 2/24/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
335.28 (292.39) |
-12.79% | Details | |
| 2/24/2026 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
23.99 (26.09) |
8.75% | Details | |
| 2/24/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Peerperform (N/A) |
20.19 (23.82) |
17.98% | Details | |
| 2/24/2026 | Alkermes | ALKS | New Coverage | Outperform (N/A) |
31.91 (48.40) |
51.68% | Details | |
| 2/24/2026 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
24.50 (27.58) |
12.57% | Details | |
| 2/23/2026 | Definium Therapeutics Inc | DFTX | New Coverage | Outperform (N/A) |
17.13 (41.99) |
145.13% | Details |
